Introduction Numerous initiatives over the past decade have targeted the problem of antibiotic overuse in the US; however, the cumulative impact of such initiatives upon recent patterns of use is not known. Objectives The aims of this study were to (1) describe general trends in outpatient antibiotic use among adults over the period 2006-2015; and (2) identify rapid shifts in use during this time period as potential indicators for key events. Methods This was an observational study set in the ambulatory setting. Patients ≥ 18 years of age were selected from the Optum Clinformatics Datamart™, a commercial insurance claims database. The outcome measures of interest were prescriptions filled/1000 enrolled individuals, by year or quarter. We used linear regression to identify trends in use over multiple years, and change-point regression to identify rapid shifts in use within individual years. 
Introduction
The problem of antibiotic overuse has persisted in the US for decades [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Previous studies have reported frequent overprescribing for certain conditions such as acute bronchitis or upper respiratory infections [2, 3, 9] , estimating that approximately 50% of antibiotic prescriptions may be unnecessary [13] . Unnecessary antibiotic use accelerates the emergence of antibiotic-resistant organisms [14] [15] [16] , is thought to cause sustained changes in the gut microbiome [17, 18] , and exposes individuals to the risk of serious adverse effects.
Several recent initiatives have attempted to address the problem of overuse in the medical setting, such as guidelines from the Infectious Diseases Society of America (IDSA), the American College of Physicians, and other specialty societies [19, 20] ; the addition of antibiotic use to the Healthcare Effectiveness Data and Information Set (HEDIS) measures; and a longstanding series of 'Get Smart' programs launched by the Centers for Disease Control and Prevention (CDC) to educate clinicians and health systems on judicious prescribing [21, 22] . In addition, major concerns have recently emerged regarding the safety of commonly used antibiotics [23] [24] [25] [26] [27] [28] . Few published studies describe the cumulative impact of such factors upon trends in antibiotic use [8, 29] .
To examine the cumulative impact of events and initiatives occurring over the past decade, we used a novel time-trend analysis technique to characterize changes in outpatient use of antibiotics from 2006 to 2015. In addition to evaluating changes in levels of use occurring over the broader time frame, we also sought to characterize rapid shifts occurring over shorter periods of time, to help explore which events may have had a more pronounced influence on patterns of use.
Methods

Data Source
We used the Optum Clinformatics Datamart™ to access insurance claims data from 2006 to 2015 [30] . This database contains inpatient and outpatient claims from commercial insurers, pharmacy dispensing information, and select patient demographics routinely collected during health insurance enrollment for approximately 15 million patients annually, including patients with Medicare Advantage. Use of de-identified data from the Optum database for research purposes was approved by the Brigham and Women's Hospital Institutional Review Board, and the need for informed consent was waived.
Patient Selection
This study included patients who were at least 18 years of age, and were continuously enrolled for ≥ 180 days prior to the start of a given calendar year to ensure a minimum duration for assessment of baseline covariates. The analysis was further restricted to patients enrolled throughout a given year to more reliably assess for changes in patterns of use. With a growing number of patients in Medicare Advantage over the time frame assessed, we anticipated a large increase in the number of individuals aged ≥ 65 years meeting the selection criteria.
Antibiotic Use
For each yearly and quarterly interval from 2006 through 2015, we assessed antibiotic use based on filled prescriptions. For each interval, rates of use were reported as filled prescriptions/1000 enrollees. Yearly rates were used to assess general trends, while quarterly rates were used for the detection of within-year changes (statistical analysis). We assessed prescription fills for all oral antibiotics, excluding antimycobacterial, antifungal, and antiviral agents. Trends and patterns of use were assessed for all antibiotics combined ('overall'), as well as individually for the most frequently prescribed classes (macrolides, penicillins, quinolones; see electronic supplementary material [ESM] 1, Table A ).
Covariates
To characterize baseline characteristics of patients in the cohort, data on age, sex, comorbidities, and measures of healthcare utilization were assessed during the baseline period (i.e. ≥ 180 days prior to the start of a given calendar year). To characterize antibiotic use among antibiotic recipients in terms of prescription sources (i.e. visit location), coded diagnosis, and common investigative procedures (i.e. chest X-rays, urinalyses, sputum cultures), we assessed healthcare encounters occurring within the week prior to and including the day of the antibiotic prescription fill; published International Classification of Diseases, Ninth Revision (ICD-9)-based algorithms were used to group specific codes into infectious diagnoses [13] (see ESM 1, Table B ). For cases in which patients visited more than one clinical site in the week prior to a prescription fill (i.e. outpatient clinic, emergency room, hospital), all sites were recorded.
Statistical Analysis
We applied a linear regression model to yearly data on antibiotic use in order to estimate general trends, stratifying this and all other assessments by age (i.e. < 65 years versus ≥ 65 years). To identify rapid shifts in use (i.e. changes in levels of use or trend reversals occurring over a short period of time) that would not be identified with simple regression, we fit quarterly data on use to a change-point regression model, generating models with zero to three potential change-points [31] [32] [33] [34] [35] . The single best model for each age group and antibiotic class was ranked based on model error (lowest error for the number of specified change-points), model efficiency (lowest AIC across all models), and statistically significant coefficients at each candidate change-point (see ESM 1, Fig. 1 ). We required change-points to be spaced at least four quarters from one another and from the ends of our data to ensure that any identified changes in trend or level were not merely due to seasonal variation in antibiotic use; seasonality was accounted for in the model by including quarter as a categorical variable (see ESM 1, Fig. 1 ). To account for multiple testing, we used a Bonferroni adjusted p value of 0.0021 (i.e. 0.05/24 models tested).
Baseline characteristics of antibiotic recipients, and covariates relating to antibiotic use, were cross-tabulated for the years 2006 and 2015. To assess for meaningful changes in covariates over this time frame, such as coded diagnoses or locations associated with antibiotic use, we used absolute standardized differences (ASDs) with a threshold of 0.10 [36] . The ASD enables comparison of the mean or prevalence of continuous or binary variables; unlike the p value, the ASD is not influenced by sample size [36] .
Results
Over the period 2006 through 2015, antibiotic use declined significantly in both age groups, decreasing by 12% for adults younger than 65 years of age (913-807 prescriptions/1000 individuals, p = 0.0001) and by 5% for adults aged ≥ 65 years (991-943 prescriptions/1000 individuals, p = 0.018) (Fig. 1 ). Age and underlying comorbidities appeared stable when comparing the first and last year of data (Table 1) . Of note, we observed a large increase in the number of individuals aged ≥ 65 years meeting the selection criteria during the overall time frame, consistent with the growing inclusion of Medicare Advantage patients in the Optum database.
Across age groups and antibiotics classes, change-point regression of quarterly data on antibiotic use by class identified a total of nine rapid shifts in use ( Fig. 2a-f (Fig. 2g, h ).
Diagnoses associated with antibiotic use remained largely unchanged over time for both age groups, with the exception (Table 2) . Among younger adults, the most common diagnoses preceding antibiotic use in 2015 were respiratory (285 prescriptions/1000 enrollees), ear/nose/ throat (186 prescriptions/1000 enrollees), and skin diagnoses (125 prescriptions/1000 enrollees). By contrast, among older adults, the most common diagnoses preceding antibiotic use in 2015 were respiratory (278 prescriptions/1000 enrollees), genitourinary (203 prescriptions/1000 enrollees), and skin diagnoses (156 prescriptions/1000 enrollees). Of note, approximately one-third of all prescriptions could not be associated with any diagnosis, given the lack of a billed healthcare encounter (see below).
We identified numerous locations for visits preceding antibiotic use (Table 2 ). For both younger and older adults, antibiotic use was most often preceded by a visit to an outpatient or office setting, with a small proportion of uses preceded by visits to the emergency room. As with diagnoses, visit location could not be ascertained for approximately one-third of antibiotic uses, which were not preceded by any billed healthcare encounter; in 2015, 238 prescriptions/1000 enrollees and 248 prescriptions/1000 enrollees could not be associated with a preceding visit, for younger and older adults, respectively. We observed significant temporal changes in visits preceding antibiotic use for older adults, with a change in the frequency of outpatient visits (− 75 prescriptions/1000 enrollees, ASD 0.15), and a rise in the frequency of emergency room visits preceding use (+ 35 prescriptions/1000 enrollees, ASD 0.15), suggesting a potential change in the source of prescriptions for older adults. Antibiotic use without a preceding billed healthcare encounter decreased significantly over time for both younger (− 75 prescriptions/1000 enrollees, ASD 0.17) and older adults (− 96 prescriptions/1000 enrollees, ASD 0.15).
With respect to investigative procedures preceding antibiotic use, testing prior to antibiotic use was infrequent, occurring prior to antibiotic use in only approximately 10% of all cases. In 2015, urinalysis was the most common test preceding antibiotic use for both younger (78 prescriptions/1000 enrollees) and older individuals (143 prescriptions/1000 enrollees). Among younger adults, we did not identify significant temporal changes in the frequency of tests conducted prior to antibiotic use, while for older adults we observed a small but significant increase in sputum cultures (+ 27, ASD 0.14) and urinalyses (+ 44, ASD 0.14) preceding use, although no change in the frequency of chest X-rays. 
Discussion
In a large cohort of commercially insured adults, we observed that antibiotic use declined significantly over the period 2006-2015. Antibiotic use decreased by 12% for adults younger than 65 years of age, and by 5% for adults ≥ 65 years of age, with much of this change occurring since 2013 for both age groups. While the direction of change observed over this time period is certainly promising, sustained efforts are required to continue reducing unnecessary antibiotic use. Our findings regarding trends in antibiotic use are consistent with several previous studies. Suda and colleagues reported decreasing use of antibiotics over the period 2006-2010 utilizing IMS Health XPonent, a prescription database that directly captures more than 70% of all prescriptions filled in community and nongovernmental mail-order pharmacies across the US, and which may be projected to provide national estimates of use [8, 37] . Although estimated overall levels of use were similar to our own for the corresponding years and age groups, the study by Suda et al. reported only a 2.8% overall decline in antibiotic use, substantially lower than the changes we observed, although possibly explained by our inclusion of more recent years of data. In a separate study of adults and children enrolled in California's public insurance program (i.e. 'Medi-Cal'), Gahbauer and colleagues reported a 15% decline in antibiotic use over the period 2006-2011, a change similar to what we identified for younger adults [38] . Notably, absolute levels of use in the study by Gahbauer et al. were much lower than ours (e.g. 461 prescriptions/1000 enrollees in 2011), consistent with the observation from several studies that have described lower rates of antibiotic prescribing to publicly versus privately insured, although the difference in levels of prescribing might also be attributable to geographic effects [39] [40] [41] [42] . Most recently, a study by Blue Cross Blue Shield regarding antibiotic use over the period 2010-2016 identified a 9% decrease in overall use, with a larger decrease among children and infants (16 and 22%) and a smaller decrease among adults (6%) [43] . In the context of these prior studies, our data contribute to the growing body of evidence, suggesting that antibiotic use in the US is in fact decreasing, although the magnitude of change and absolute levels of use may differ based on age group, insurance type, and geography.
Survey-based assessments of antibiotic use have also provided valuable insight into antibiotic prescribing for specific indications, such as numerous studies based on the CDC's National Hospital Ambulatory Medical Care Survey (NHAMCS) and National Ambulatory Medical Care Survey (NAMCS) [1-4, 9, 15] . However, given the visit-based structure of NAMCS and NHAMCS, such studies are typically confined to estimating rates of prescribing among indication-specific visits rather than populations of patients, making comparison with our data more difficult. However, Lee and colleagues used the Medical Expenditure Panel Survey (MEPS), one of the nationally representative surveys that includes person-level data [44] . In contrast to what we reported, Lee et al. reported no change in antibiotic use over the period 2000-2010 among adults younger than 65 years of age, and a 30% increase in antibiotic use among adults ≥ 65 years of age [29] . Absolute rates of use reported were also substantially lower than those in our study for both age groups: 354 prescriptions/1000 for adults younger than 65 years of age, and 480 prescriptions/1000 for adults ≥ 65 years of age. These discrepancies might be explained by recall bias or aspects of survey design leading to underestimates of use. In support of this notion, a validation study comparing the agreement between MEPS and Medicare Part D claims determined that short-term medications such as antibiotics are prone to substantial underreporting in MEPS, concluding that the data source is better suited for monitoring the use of chronic medications [45] . Moreover, our estimates of use are in closer agreement with studies based on IMS Health Xponent, which, as described above, directly measures use at a national level [8, 11, 42] .
Through our analysis of data on quarterly use, we identified specific time points associated with rapid shifts in antibiotic use, suggestive of the influence of one or more temporally associated factors. Although we cannot definitively link any changes to specific events, the identified shifts are hypothesis-generating. For instance, we observed a rapid downward shift in macrolide use in 2013 for both age groups, possibly reflecting the impact of enhanced warnings issued by the US FDA regarding cardiovascular risks, or the impact of a widely publicized article by Ray et al., published in 2012, reporting increased risk of sudden cardiac death with azithromycin [28] . With quinolones, we observed a shift associated with trend reversal in use following the second quarter of 2008 (i.e. change from increasing to decreasing use), which approximately coincided with the release of black-box warnings on risk of tendon rupture and tendinopathy with quinolones, issued by the FDA [24] . Other factors pre-dating the addition of black-box warnings may have also contributed to this decline in use, such as treatment guidelines for sexually transmitted diseases released by the CDC in 2007, explicitly discouraging the use of quinolones for Neisseria gonorrhea given widespread resistance [46] . In addition, the 2008 downturn in the economy could have also prompted switches to cheaper antibiotics or healthcare avoidance, possibly contributing to the observed shift, although we would have expected this effect to have been reflected across all drug classes [47, 48] . As a final consideration in the trends for quinolones, we identified a transient but statistically significant rise in the first quarter of 2012 for older patients; changes in drug prices with the emergence of generic versions of Levaquin might have contributed to this rise in use, as might the latepeaking influenza season, although the latter was not considered to be particularly severe [49, 50] . With penicillins, we observed no significant change in levels or trends of use among younger adults, while, for older adults, we observed an initial decline followed by a trend reversal early in 2009, with a positive, statistically significant trend in use. This rise might reflect substitution of quinolones or macrolides for penicillins due to perceived issues with safety or cost. In total, we identified not only gradual changes in antibiotic use over the period 2006-2015 but also a number of rapid shifts in use that suggest the influence of key drivers of change.
In assessing the evolving context of antibiotic use, an unexpected finding was that nearly one-third of filled prescriptions could not be associated with a healthcare encounter, suggesting the possibility of remote management via phone or e-mail. To date, only one other study has described this phenomenon, albeit with lower rates of so-called 'phantom' visits than what we found (15% of prescriptions vs. 30% of prescriptions in our study were not preceded by a billed visit), perhaps explained by the authors' focus on a higher acuity population (post-myocardial infarction Medicare beneficiaries), whom clinicians might be more likely to manage in a traditional clinical encounter [51] . We found that the frequency of prescribing occurring without a claim for a clinical encounter has decreased significantly over the past decade, suggesting either better billing capture of nonface-to-face encounters, or more careful prescribing on the part of clinicians. In evaluating changes in antibiotic use by condition, we did not observe significant changes in the frequency of antibiotic prescribing for respiratory or ear/ nose/throat conditions, which have been the frequent focus of stewardship efforts [13] .
This study has a number of limitations. First, while overall levels of use appear to be declining in the population examined, we have not examined appropriateness of use or utilization trends for specific indications. Second, while our data are likely to accurately reflect overall trends in use among commercially insured patients in the US, the magnitude of these changes are likely different in other populations such as children or those with public insurance only. However, Census data indicates that 90.9% of the US population in recent years has insurance, with 67.2% of those with insurance being privately insured, suggesting the findings would generalize to a large proportion of the US population [52] . Furthermore, the specific time points where we have identified significant shifts to have occurred are merely hypothesis-generating; some of these hypotheses, such as the impact of the azithromycin-specific FDA warning were based on the observation that azithromycin constituted the majority of the macrolide class. It is possible that other events not discussed here, or publicly knowable, may have been responsible for the changes. Although our analysis of patient characteristics did not suggest changes in demographics were responsible for the observed trends, we acknowledge that comparison of first and last years may not fully capture the dynamic changes occurring throughout the entire time period. While there may have been some correlation in prescribing patterns by clinician or patient, our analysis did not capture this aspect. Finally, our findings do not generalize to other countries, in which trends may differ. In the UK, for instance, outpatient antibiotic utilization has increased steadily since 2007, while, in contrast, levels in Sweden have declined [53] .
Conclusions
We found steadily declining rates of antibiotic use in the US in recent years, with a gradual overall decline punctuated by accelerated, abrupt changes suggestive of effects from other social or economic factors. Future research should aim to more definitively identify the reasons underlying change, and to characterize trends in populations not assessed in this study.
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